Canaccord Genuity Maintains Buy on Castle Biosciences, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Castle Biosciences (NASDAQ:CSTL) but lowers the price target from $35 to $42.
October 29, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Castle Biosciences but lowers the price target from $35 to $42, indicating continued confidence in the stock despite a revised target.
The maintenance of a Buy rating suggests positive sentiment towards Castle Biosciences, which could support the stock price. However, the lowered price target may temper expectations, indicating a more cautious outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100